Phase 1/2a, dose-escalation, safety and proof of concept study of intravesical DTA-H19 [BC 819] in patients with superficial bladder cancer.

Trial Profile

Phase 1/2a, dose-escalation, safety and proof of concept study of intravesical DTA-H19 [BC 819] in patients with superficial bladder cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs BC 819 (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Jan 2008 Status changed from in progress to completed.
    • 27 Jun 2007 Status changed from recruiting to in progress.
    • 12 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top